GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neumora Therapeutics Inc (NAS:NMRA) » Definitions » Debt-to-Equity

Neumora Therapeutics (Neumora Therapeutics) Debt-to-Equity : 0.01 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neumora Therapeutics Debt-to-Equity?

Neumora Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $3.49 Mil. Neumora Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.94 Mil. Neumora Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $424.54 Mil. Neumora Therapeutics's debt to equity for the quarter that ended in Mar. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Neumora Therapeutics's Debt-to-Equity or its related term are showing as below:

NMRA' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.02   Med: -0.01   Max: 0.01
Current: 0.01

During the past 5 years, the highest Debt-to-Equity Ratio of Neumora Therapeutics was 0.01. The lowest was -0.02. And the median was -0.01.

NMRA's Debt-to-Equity is ranked better than
99.91% of 1072 companies
in the Biotechnology industry
Industry Median: 0.14 vs NMRA: 0.01

Neumora Therapeutics Debt-to-Equity Historical Data

The historical data trend for Neumora Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neumora Therapeutics Debt-to-Equity Chart

Neumora Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
- -0.02 -0.01 -0.02 0.01

Neumora Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A -0.01 0.01 0.01 0.01

Competitive Comparison of Neumora Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Neumora Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neumora Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neumora Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Neumora Therapeutics's Debt-to-Equity falls into.


Neumora Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Neumora Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.378 + 1.853) / 469.076
=0.01

Neumora Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.491 + 0.938) / 424.542
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neumora Therapeutics  (NAS:NMRA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Neumora Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Neumora Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Neumora Therapeutics (Neumora Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neumora Therapeutics Inc (NAS:NMRA) » Definitions » Debt-to-Equity
Comparable Companies
ACLX BEAM VCEL RCKT VCYT TGTX SWTX HRMY CBAY IDYA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
490 Arsenal Way, Suite 200, Watertown, MA, USA, 02472
Website
https://www.neumoratx.com
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
Executives
Kristina Burow director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Xii, Llc 10 percent owner 8755 W HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Henry O Gosebruch director, officer: President & CEO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Arch Venture Fund X, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Amgen Inc 10 percent owner ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Arch Venture Partners X Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Viii, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Daljit Singh Aurora officer: Chief Strategy Officer C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Arch Venture Fund Xii, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Xii, L.p. 10 percent owner 8755 W HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Joshua Pinto officer: Chief Financial Officer C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Alaa Halawa director C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Carol Y. Suh officer: Chief Operating Officer C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472